3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Sanders
D B
DB
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity; D000284:Administration, Oral; D000077770:Amifampridine; D000818:Animals; D005500:Follow-Up Studies; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000188:drug therapy*; D051379:Mice; D009157:Myasthenia Gravis / Q000188:drug therapy; D015221:Potassium Channels / Q000502:physiology; D013997:Time Factors
D015221:Potassium Channels; D015761:4-Aminopyridine; D000077770:Amifampridine